Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Achieve Life Sciences Inc (ACHV)
NASDAQ:ACHV
RESEARCH TOOLSreports
Holding ACHV?
Track your performance easily
ACHV Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.03 - $5.98
Previous Close$4.4
Volume9.86K
Average Volume (3M)224.46K
Market Cap
$155.22M
Enterprise Value$107.43M
Total Cash (Recent Filing)$61.31M
Total Debt (Recent Filing)$17.64M
Price to Earnings (P/E)―
Beta1.73
Next Earnings
Nov 06, 2024EPS Estimate
-$0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.10
Shares Outstanding34,341,303
10 Day Avg. Volume76,171
30 Day Avg. Volume224,457
Standard Deviation0.25
R-Squared0.10
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)3.58
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-7.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-4.45
Forecast
1Y Price Target
$16.40Price Target Upside262.83% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Achieve Life Sciences News
PremiumCompany Announcements
Achieve Life Sciences Announces Leadership Shake-Up and Board Reshuffle
PremiumPre-Earnings
Is ACHV a Buy, Before Earnings?
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessPositive results from the ORCA-2 and ORCA-3 Phase 3 studies met primary and secondary endpoints, supporting the treatment's efficacy and highlighting its potential for market success.
Financial HealthAchieve reported a strengthened balance sheet through financing, which extends the cash runway well into the future, indicating a solid financial position for sustained operations.
Regulatory MilestonesFDA alignment secures the next steps for Achieve to submit an NDA for cytisinicline, showcasing progress in the regulatory process and potential market approval.
Bears Say
Drug Approval DelaysAnticipate a one-year delay in the approval and launch of cytisinicline due to FDA's demand for more extensive safety data.
Regulatory ChallengesFDA insists on an additional long-term exposure study for cytisinicline, questioning the validity of the current safety data.
Stock ImpactAnalyst revises the price target for the company's stock downward from $35 to $25 based on anticipated approval delays for cytisinicline.
---
Ownership Overview
12.92% Insiders
10.74% Mutual Funds
30.04% Other Institutional Investors
46.31% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ACHV FAQ
What was Achieve Life Sciences Inc’s price range in the past 12 months?
Achieve Life Sciences Inc lowest stock price was $3.03 and its highest was $5.98 in the past 12 months.
What is Achieve Life Sciences Inc’s market cap?
Currently, no data Available
When is Achieve Life Sciences Inc’s upcoming earnings report date?
Achieve Life Sciences Inc’s upcoming earnings report date is Nov 06, 2024 which is in 48 days.
How were Achieve Life Sciences Inc’s earnings last quarter?
Achieve Life Sciences Inc released its earnings results on Aug 13, 2024. The company reported -$0.25 earnings per share for the quarter, missing the consensus estimate of -$0.239 by -$0.011.
Is Achieve Life Sciences Inc overvalued?
According to Wall Street analysts Achieve Life Sciences Inc’s price is currently Undervalued.
Does Achieve Life Sciences Inc pay dividends?
Achieve Life Sciences Inc does not currently pay dividends.
What is Achieve Life Sciences Inc’s EPS estimate?
Achieve Life Sciences Inc’s EPS estimate is -$0.27.
How many shares outstanding does Achieve Life Sciences Inc have?
Achieve Life Sciences Inc has 34,341,305 shares outstanding.
What happened to Achieve Life Sciences Inc’s price movement after its last earnings report?
Achieve Life Sciences Inc reported an EPS of -$0.25 in its last earnings report, missing expectations of -$0.239. Following the earnings report the stock price went up 0.459%.
Which hedge fund is a major shareholder of Achieve Life Sciences Inc?
Currently, no hedge funds are holding shares in ACHV
---
Achieve Life Sciences Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$16.40 (262.83% Upside)
$16.40 (262.83% Upside)
Blogger Sentiment
Bullish
ACHV Sentiment 100%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 0.2%
Last 30 Days ▼ 0.2%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-3.08%
12-Months-Change
Fundamentals
Return on Equity
-105.95%
Trailing 12-Months
Asset Growth
124.07%
Trailing 12-Months
Company Description
Achieve Life Sciences Inc
Achieve Life Sciences, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of cytisinicline for smoking cessation. Its products, cytisine, is a plant-based alkaloid with a binding affinity to the nicotinic acetylcholine receptor. The company was founded in October 1991 and is headquartered in Vancouver, Canada.
---
ACHV Earnings Call
Q2 2024
0:00 / 0:00
---
ACHV Stock 12 Month Forecast
Average Price Target
$16.40
▲(262.83% Upside)
Technical Analysis
Best Analysts Covering ACHV
1 Year
1 Year Success Rate
12/35 ratings generated profit
1 Year Average Return
-13.09%
reiterated a buy rating last month
Copying Michael Higgins's trades and holding each position for 1 Year would result in 34.29% of your transactions generating a profit, with an average return of -13.09% per trade.
---